CellSeed Inc. (JP:7776)
:7776
7776 Stock Chart & Stats
¥259.00
-¥7.00(-1.73%)
At close: 4:00 PM EST
¥259.00
-¥7.00(-1.73%)
Day’s Range― - ―
52-Week Range¥231.00 - ¥668.00
Previous CloseN/A
Volume900.50K
Average Volume (3M)621.90K
Market Cap
¥11.77B
Enterprise Value¥7.80B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.30
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.31
Shares Outstanding38,474,320
10 Day Avg. Volume981,780
30 Day Avg. Volume621,903
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)7.08
Price to Sales (P/S)107.39
P/FCF Ratio-8.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Healthy Gross Margins / Unit EconomicsDespite operational losses, gross margins near 48–69% indicate strong unit economics for cell-based products. This suggests that if fixed costs and scale issues are addressed, the core product line could convert to sustainable profits as revenue recovers or production scales.
Low Financial LeverageConservative debt levels reduce near-term interest burden and provide financial flexibility to raise cash via equity or debt without heavy leverage strain. This structural balance-sheet buffer helps the company manage funding rounds and preserve optionality during a multi-quarter turnaround.
Specialized Regenerative Medicine PlatformA focused cell-sheet engineering platform positions the company in a high-barrier niche of regenerative medicine. Specialized IP, manufacturing expertise and service capabilities support durable differentiation, potential partnership deals, and recurring service revenue as the sector matures.
Bears Say
Sharp Revenue DeteriorationA 56.7% revenue decline materially reduces operating scale, undermines absorption of fixed R&D and production costs, and lengthens the path to profitability. Sustained top-line weakness forces deeper restructuring or additional financing to preserve operations.
Persistent Cash Burn And Negative FCFConsistent negative operating and free cash flow demonstrate the business cannot self-fund growth or operations. This structural cash burn increases reliance on external financing, heightens dilution risk, and constrains long-term strategic investments without capital raises.
Very Large Operating Losses And Equity ErosionMassive operating losses and a collapsing net margin drive deeply negative returns on equity and have already shrunk shareholder equity. This erodes investor capital, limits borrowing capacity, and creates a durable funding overhang unless profitability is restored or substantial external capital is secured.
CellSeed Inc. News
7776 FAQ
What was CellSeed Inc.’s price range in the past 12 months?
CellSeed Inc. lowest stock price was ¥231.00 and its highest was ¥668.00 in the past 12 months.
What is CellSeed Inc.’s market cap?
CellSeed Inc.’s market cap is ¥11.77B.
When is CellSeed Inc.’s upcoming earnings report date?
CellSeed Inc.’s upcoming earnings report date is May 18, 2026 which is in 51 days.
How were CellSeed Inc.’s earnings last quarter?
CellSeed Inc. released its earnings results on Feb 13, 2026. The company reported -¥7.31 earnings per share for the quarter, missing the consensus estimate of N/A by -¥7.31.
Is CellSeed Inc. overvalued?
According to Wall Street analysts CellSeed Inc.’s price is currently Overvalued.
Does CellSeed Inc. pay dividends?
CellSeed Inc. does not currently pay dividends.
What is CellSeed Inc.’s EPS estimate?
CellSeed Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CellSeed Inc. have?
CellSeed Inc. has 38,474,320 shares outstanding.
What happened to CellSeed Inc.’s price movement after its last earnings report?
CellSeed Inc. reported an EPS of -¥7.31 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.305%.
Which hedge fund is a major shareholder of CellSeed Inc.?
Currently, no hedge funds are holding shares in JP:7776
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellSeed Inc.
CellSeed Inc. develops cell sheet regenerative medicines. It is involved in the research, development, and commercialization of cell-sheet regenerative medicine products, such as epithelial cell sheet for esophageal regeneration, regenerated cartilage sheet, and chondrocyte sheet for the treatment of knee osteoarthritis. The company also offers UpCell, a temperature-responsive cell cultureware for cell-sheet engineering; RepCell, a temperature-responsive cell cutureware for cell collection; and HydroCell, a low cell binding cultureware. In addition, it provides peripheral equipment, including ThermoPlate III, a heating element made by a transparent glass plate; and cellZscope, an automated cell monitoring system, as well as contract development and manufacturing services. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
StemCell Institute
―
Japan Tissue Engineering Co., Ltd.
―